Literature DB >> 31014769

Wide-Field Swept-Source OCT and Angiography in X-Linked Retinoschisis.

Ian C Han1, S Scott Whitmore2, D Brice Critser2, Sun Young Lee2, Adam P DeLuca2, Heather T Daggett2, Louisa M Affatigato2, Robert F Mullins2, Budd A Tucker2, Arlene V Drack2, Edwin M Stone2.   

Abstract

PURPOSE: Retinal vascular and structural changes, particularly outside of the central macula, are not well characterized in X-linked retinoschisis (XLRS). We aim to describe wide-field swept-source OCT (SS-OCT) and swept-source OCT angiography (SS-OCTA) findings in XLRS.
DESIGN: Retrospective, cross-sectional study at a tertiary referral center. PARTICIPANTS: Nine consecutive male patients with molecularly confirmed XLRS.
METHODS: All patients underwent complete ophthalmic examination with multimodal imaging, including SS-OCT with SS-OCTA (PLEX Elite 9000; Carl-Zeiss Meditec Inc., Dublin, CA). Images were then reviewed by 2 retinal specialists as independent graders to determine the frequency and distribution of retinal structural and vascular abnormalities. MAIN OUTCOME MEASURES: Structural and vascular abnormalities seen on SS-OCT and SS-OCTA in patients with XLRS, with attention to the retinal layers involved, the regional distribution of schitic spaces in the posterior pole, and vascular abnormalities within the superficial and deep capillary plexuses.
RESULTS: Eighteen eyes from 9 male patients (mean age, 20 years; range 9-40) with molecularly confirmed XLRS were included. Median best-corrected visual acuity measured 20/63 (range, 20/25-10/300). A total of 17 of 18 eyes (94.4%) were noted to have schitic spaces on SS-OCT, and these were observed to be predominantly within the inner nuclear layer in all 17 eyes. A regional variation in the distribution of cysts was noted, with schitic spaces within the ganglion cell layer (13/17 eyes; 76.5%) observed to be perifoveal and those within the outer nuclear layer (8/17 eyes, 47.1%) observed to be mostly extramacular. All eyes had vascular abnormalities on SS-OCTA, including an irregular foveal avascular zone and flow loss within the deep capillary plexus corresponding to the distribution of the schisis.
CONCLUSIONS: Wide-field SS-OCT and SS-OCTA provide detailed visualization of structural and vascular changes in XLRS and may be helpful for monitoring disease progression or treatment response in clinical trials for the disease.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 31014769     DOI: 10.1016/j.oret.2018.09.006

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  5 in total

1.  Biomarkers for Nonexudative Age-Related Macular Degeneration and Relevance for Clinical Trials: A Systematic Review.

Authors:  Vivienne Fang; Maria Gomez-Caraballo; Eleonora M Lad
Journal:  Mol Diagn Ther       Date:  2021-08-25       Impact factor: 4.074

2.  Comparison of standard and "innovative wide-field" optical coherence tomography images in assessment of vitreoretinal interface in proliferative diabetic retinopathy: A pilot study.

Authors:  Divyansh Kailashchandra Mishra; Mahesh P Shanmugam; Rajesh Ramanjulu; Pradeep Sagar
Journal:  Indian J Ophthalmol       Date:  2021-01       Impact factor: 1.848

3.  Clinical and Genetic Study of X-Linked Juvenile Retinoschisis in the Czech Population.

Authors:  Bohdan Kousal; Lucia Hlavata; Hana Vlaskova; Lenka Dvorakova; Michaela Brichova; Zora Dubska; Hana Langrova; Andrea L Vincent; Lubica Dudakova; Petra Liskova
Journal:  Genes (Basel)       Date:  2021-11-18       Impact factor: 4.096

Review 4.  Approach to inherited retinal diseases.

Authors:  Dhanashree Ratra; Sengul Ozdek; Munispriyan Raviselvan; Sailaja Elchuri; Tarun Sharma
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

Review 5.  Exudative maculopathy in presumed X-linked retinoschisis with review of literature.

Authors:  Srishti Ramamurthy; Deepika C Parameswarappa; Srikanta K Padhy; Brijesh Takkar
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.